MDT-AP-2497
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 60
- os_event
- false
- age_years
- 5.2
- sex
- M
- new_clusters
- C1
- umap1_2d
- 4.065636816
- umap2_2d
- -0.847213241
- umap1_3d
- -0.504862865
- umap2_3d
- -3.789215678
- umap3_3d
- 0.04024056
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.720
- G2M_CHECKPOINT+0.680
- MYC_TARGETS_V1+0.620
- MYC_TARGETS_V2+0.480
- MTORC1_SIGNALING+0.400
- MITOTIC_SPINDLE+0.380
- DNA_REPAIR+0.360
- OXIDATIVE_PHOSPHORYLATION+0.340
- TGF_BETA_SIGNALING+0.330
- ANDROGEN_RESPONSE+0.290
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.360
- MYOGENESIS-0.360
- ALLOGRAFT_REJECTION-0.340
- COMPLEMENT-0.340
- HYPOXIA-0.330
- IL6_JAK_STAT3_SIGNALING-0.330
- COAGULATION-0.320
- INFLAMMATORY_RESPONSE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3297 | Med | Medulloblastoma | 0.962 |
| 2 | MDT-AP-0167 | Med | Medulloblastoma | 0.918 |
| 3 | MDT-AP-2110 | Med | Medulloblastoma | 0.916 |
| 4 | MNG1063 | — | — | 0.908 |
| 5 | MDT-AP-0002 | Med | Medulloblastoma | 0.907 |
| 6 | MDT-AP-0164 | Med | Medulloblastoma | 0.906 |
| 7 | BS_G23JJAZY | EPN | Supratentorial EPN | 0.902 |
| 8 | SRR12202462 | — | — | 0.901 |
| 9 | R143 | — | — | 0.895 |
| 10 | BS_052PZFMK | high-grade glioma | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.720 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.680 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.620 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |